On 9 September 2025, AS LHV Group carried out an issue of Tier 2 subordinated notes in the total nominal amount of EUR 80,000,000 (the “Notes”) in the international markets. The settlement date of the Notes is 16 September 2025. The Notes are issued in bearer form with a denomination of EUR 100,000, with increments of EUR 1,000. The Notes mature on 16 September 2035 and have a first call date on 16 September 2030. Until the first call date, the Notes bear interest at a fixed rate of 5.5% per annum, payable ...

Coop Pank’s financial results in August 2025: In August, number of the bank's clients increased by 1,700 and number of active clients decreased by 300. By the end of the month number of clients reached 221,000 and number of active clients reached 103,800. Over the year, customer base has grown by 11%. Volume of the bank's customer deposits decreased by 4 million euros and reached 1.92 billion euros by the end of month. Deposits of corporate customers decreased by 6 million euros and deposits of private cust ...

TGS’ presentation for the Pareto Securities Energy Conference 2025 is available on www.newsweb.no or TGS’ website www.tgs.com. CEO Kristian Johansen will present today at 15:55 CEST. For more information, visit TGS.com or contact: Bård Stenberg VP IR & Communication Mobile: +47 992 45 235 investor@tgs.com Attachment Pareto Securities Energy Conference 2025 ...

Faraday Future Successfully Completes Nasdaq One-Year Compliance Monitoring Period as it Fully Met All Compliance Requirements During the Period, Returns to a Fully Normal Listed-Company Status Faraday Future Successfully Completes Nasdaq One-Year Compliance Monitoring Period as it Fully Met All Compliance Requirements During the Period, Returns to a Fully Normal Listed-Company Status Upholding its principles of “no further reverse stock splits” and prudent equity issuances, the Company is committed to ...

Core Viewpoint - Dianthus Therapeutics, Inc. has announced the pricing of an upsized underwritten public offering of 6,487,879 shares of common stock at $33.00 per share, along with pre-funded warrants for 1,112,121 shares at $32.999 each, aiming to raise approximately $251 million before expenses [1][2]. Group 1: Offering Details - The offering includes a total of 6,487,879 shares of common stock priced at $33.00 each and pre-funded warrants for 1,112,121 shares priced at $32.999 each, with an exercise price of $0.001 per share [1]. - The expected gross proceeds from the offering are approximately $251 million, excluding underwriting discounts and commissions [1]. - The offering is set to close on September 11, 2025, subject to customary closing conditions, and underwriters have a 30-day option to purchase an additional 1,140,000 shares [1]. Group 2: Use of Proceeds - Dianthus intends to utilize the net proceeds from the offering to advance its preclinical and clinical development activities, as well as for working capital and general corporate purposes [2]. Group 3: Company Overview - Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing next-generation antibody complement therapeutics for severe autoimmune diseases [5]. - The company is based in New York City and Waltham, Massachusetts, and is led by an experienced team of biotech and pharma executives [5].

SOMPO uses Radar to accelerate data-driven management across pricing, underwriting and portfolio optimization, and with Sompo Direct Insurance Inc. implementing Radar as its rate calculation engine.TOKYO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- WTW (NASDAQ: WTW), a leading global advisory, broking and solutions company, and Sompo Holdings, Inc., one of Japan’s leading insurance groups, today announced a global partnership to deploy WTW’s Radar technology across SOMPO Group. This marks the first global agreement ...

VANCOUVER, British Columbia, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Prime Mining Corp. (“Prime” or the “Company”) (TSX: PRYM) (OTCQX: PRMNF) (Frankfurt: O4V3) announced today that it has filed its notice of meeting and management information circular (the “Circular”) with securities regulators in connection with the special meeting (the “Meeting”) of the holders (the “Shareholders”) of common shares of the Company (the “Prime Shares”), the holders (the “Option Holders”) of options to purchase Prime Shares (the ...

Core Viewpoint - Rapport Therapeutics, Inc. has announced a public offering of 9,615,385 shares at a price of $26.00 per share, aiming to raise approximately $250 million in gross proceeds before expenses [1][3]. Company Overview - Rapport Therapeutics is a clinical-stage biotechnology company focused on developing small molecule precision medicines for neurological and psychiatric disorders [5]. - The company utilizes a RAP technology platform based on pioneering discoveries related to receptor associated proteins (RAPs) in the brain, which allows for a differentiated approach in drug discovery [5]. - The lead investigational drug, RAP-219, targets specific regions of the brain and is being pursued for conditions such as drug-resistant focal onset seizures, bipolar mania, and diabetic peripheral neuropathic pain [5]. Offering Details - The offering includes a 30-day option for underwriters to purchase an additional 1,442,307 shares at the public offering price [1]. - The offering is expected to close around September 11, 2025, pending customary closing conditions [1]. - Goldman Sachs, Jefferies, TD Cowen, and Stifel are acting as joint book-running managers for the offering [2].

New York, NY, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Trailblazer Acquisition Corp. (the “Company”) announced today the pricing of its upsized initial public offering of 24,000,000 units at a price of $10.00 per unit. The units are expected to be listed on The Nasdaq Global Stock Market LLC (“Nasdaq”) and begin trading on September 10, 2025, under the ticker symbol “BLZRU.” Each unit consists of one Class A ordinary share and one-third of one redeemable warrant, each whole warrant entitling the holder thereof t ...

MELBOURNE, Australia and INDIANAPOLIS, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces it has dosed the first patient in a Phase 3 clinical trial aimed at expanding the indications for Illuccix® and Gozellix® (kits for the preparation of gallium-68 (68Ga) gozetotide injection) to include prostate cancer diagnosis. BiPASS™ (Biopsy of the Prostate Avoidance Stratification Study1) is the first registration-enabling study to evaluate whether the ...